Breaking Finance News

ValuEngine upgraded Immunomedics, Inc. (NASDAQ:IMMU) to Hold in a report released today.

ValuEngine has upgraded Immunomedics, Inc. (NASDAQ:IMMU) to Hold in a report released on 06/02/2017.

Just yesterday Immunomedics, Inc. (NASDAQ:IMMU) traded 1.95% higher at $7.88. Immunomedics, Inc.’s 50-day moving average is $12.04 and its 200-day moving average is $8.88. The last stock price is down 23.87% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 2,178,752 shares of IMMU traded hands, down from an average trading volume of 2,690,790

Recent Performance Chart

Immunomedics, Inc. (NASDAQ:IMMU)

Immunomedics, Inc. has 52 week low of $2.02 and a 52 week high of $14.48 and has a market cap of $0.

In addition to ValuEngine reporting its target price, a total of 1 firm has reported on the stock. The consensus target price is $5.00 with 2 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Immunomedics, Inc. (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.